1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Basilea Looks To Progress Cancer Pipeline As It Expands Zevtera Use

Ceftobiprole Approved In China

 
• By John Davis

Switzerland’s Basilea Pharmaceutica is progressing its lead oncology candidates and a second late-stage US clinical trial of ceftobiprole in difficult-to-treat infections.    

Meticillin Resistant Staphylococcus aureus
Meticillin-Resistant S aureus (MRAS) • Source: Shutterstock

Key priorities for Switzerland’s Basilea Pharmaceutica Ltd. this year include pursuing the US Phase III study of the fifth-generation cephalosporin ceftobiprole in serious infections, obtaining interim clinical trial results for its lead oncology candidates derazantinib and lisavanbulin, and helping partner CR Gosun launch ceftobiprole in China.

The Basel, Switzerland-based drug development company expects to complete enrolment into the Phase III ERADICATE study of the fifth-generation cephalosporin,...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Anti-infective

Moderna Flunks Pivotal CMV Trial, But Read-Through Unlikely

 
• By Alaric DeArment

The company is discontinuing congenital CMV development for its mRNA-1647 vaccine but still running a Phase II trial in bone marrow transplant patients.

Phase III Success For AiCuris’s Herpes Simplex Treatment

 
• By Andrew McConaghie

The German company is now gearing up for a US filing for a product that overcomes drug resistance issues in herpes simplex, and which it believes could transform its business.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Enanta Plans Phase III Trial Of Zelicapavir Despite Primary Endpoint Miss

 
• By Alaric DeArment

The company announced Phase IIb results for the RSV drug that showed positive data across multiple key secondary endpoints, some of which could serve as a primary endpoint in Phase III.

More from Therapy Areas

A Week Is A Long Time In Biotech, Just Ask Galecto

 
• By Kevin Grogan

A long time on the ropes, the US firm is now well-financed to advance potential candidates for essential thrombocythemia and myelofibrosis into the clinic.

AnaptysBio Scraps Rosnilimab Ulcerative Colitis Trial After Phase II Miss

 
• By Sushmita Panda

The biopharma plans to advance the PD-1 agonist in rheumatoid arthritis despite its failure in ulcerative colitis.

Neurocrine’s Depression Drug Misses In Phase II

 
• By Andrew McConaghie

Small study fails to turn up efficacy signals in the major depressive disorder candidate, leaving Neurocrine with one remaining depression candidate in development.